Statin Use and Reduced Risk of Sudden Sensorineural Hearing Loss in Type 2 Diabetes
Otolaryngology–Head and Neck Surgery · 2025
DOI: 10.1002/ohn.1214 ↗At a glance
Journal article in Otolaryngology–Head and Neck Surgery, 2025. Written by Tse-Hsi Li and 5 co-authors. Institution: Department of Otorhinolaryngology, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan. Major MEDLINE topics: Diabetes Mellitus, Type 2, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Hearing Loss, Sensorineural, Hearing Loss, Sudden. Cited 1 times so far (Crossref); 50 references.
Topics: Diabetes mellitus
Abstract (original language)
Objective
To examine the association between statin use and the risk of sudden sensorineural hearing loss (SSNHL) in patients with type 2 diabetes (T2D), focusing on statin type, dosage, and treatment duration. Study Design Retrospective cohort study.
Setting
Taiwan National Health Insurance Research Database.
Methods
We analyzed T2D patients diagnosed between 2008 and 2019, stratified into statin users and nonusers of lipid‐lowering therapy. Propensity score matching was used to balance baseline characteristics. Multivariable Cox regression, adjusted for competing risks, assessed the association between statin use and SSNHL risk, as well as all‐cause mortality. Statin exposure was analyzed based on cumulative and daily doses.
Results
The study cohort included 66,120 statin users and 66,120 nonusers. Statin use was associated with a significantly lower SSNHL risk (adjusted hazard ratio [aHR], 0.83; 95% CI, 0.74‐0.92; P = .0008) and reduced all‐cause mortality (aHR, 0.55; 95% CI, 0.52‐0.57; P < .0001). A dose‐response relationship was observed, with higher cumulative defined daily doses (cDDDs) linked to progressively lower SSNHL risk. Hydrophilic statins, particularly rosuvastatin, showed stronger protective effects compared to lipophilic statins.
Conclusion
Statin use in T2D patients is associated with reduced SSNHL risk and all‐cause mortality, with dose‐dependent effects. These findings suggest the potential otoprotective benefits of statins and emphasize the importance of personalized therapy for managing both hearing and cardiovascular health in this high‐risk population.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Otorhinolaryngology, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan.
- Department of Emergency Medicine, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan.
- Graduate Institute of Business Administration, College of Management, Fu Jen Catholic University, Taipei, Taiwan.
- Artificial Intelligence Development Center, Fu Jen Catholic University, Taipei, Taiwan.
- Department of Food Nutrition and Health Biotechnology, College of Medical and Health Science, Asia University, Taichung, Taiwan.
- Division of Radiation Oncology, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan.
Cite
APA
Li, T. H., Shiu, J. S., Chen, W. M., Shia, B. C., Wu, S. Y., & Lin, H. C. (2025). Statin Use and Reduced Risk of Sudden Sensorineural Hearing Loss in Type 2 Diabetes. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.1214
Vancouver
Li TH, Shiu JS, Chen WM, Shia BC, Wu SY, Lin HC. Statin Use and Reduced Risk of Sudden Sensorineural Hearing Loss in Type 2 Diabetes. Otolaryngology–Head and Neck Surgery. 2025. doi:10.1002/ohn.1214
BibTeX
@article{Li2025,
author = {Li, Tse-Hsi and Shiu, Jr-Shiang and Chen, Wan-Ming and Shia, Ben-Chang and Wu, Szu-Yuan and Lin, Hsuan-Chih},
title = {Statin Use and Reduced Risk of Sudden Sensorineural Hearing Loss in Type 2 Diabetes},
journal = {Otolaryngology–Head and Neck Surgery},
year = {2025},
doi = {10.1002/ohn.1214}
}
EUVIMED